Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong ...
The parent of bankESB and TruNorth Bank will end its 157-year history as a depositor-owned institution, in part to fund the ...
8h
A drug already in human trials could reverse tooth loss by 2030, a condition that affects millions
Japanese biotech drug aims to reverse tooth loss by regrowing teeth. Here's how TRG-035 works, where trials stand and when it ...
Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...
A series of biotech acquisitions transpired in under 9 months — totaling more than $3.5 billion. The drugs behind them target ...
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.
In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...
Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant ...
Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...
Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...
David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results